Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3934MR)

This product GTTS-WQ3934MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3934MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13946MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-2810
GTTS-WQ10138MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LAG-525
GTTS-WQ1498MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ4921MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ9138MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMGN-289
GTTS-WQ10494MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY-2951742
GTTS-WQ5275MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD124
GTTS-WQ15507MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA UCB-7665
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW